Radiotherapy versus Surgery in Early-Stage HPV-Positive Oropharyngeal Cancer

다국어 초록 (Multilingual Abstract)

Purpose This study aimed to compare the outcomes of primary radiotherapy (RT) versus surgery in early-stage human papilloma virus–positive oropharyngeal squamous cell carcinoma (hpv+OPC), and investigate the preoperative clinical factors that can predict the requirement for postoperative adjuvant treatment.
Materials and Methods This multicenter study included 166 patients with American Joint Committee on Cancer 8th edition-Stages I-II hpv+OPC. Sixty (36.1%) and 106 (63.9%) patients underwent primary (concurrent chemo)radiotherapy [(CC)RT] and surgery, respectively. Seventy-eight patients (73.6%) in the surgery group received postoperative (CC)RT.
Results With a median follow-up of 45.6 months for survivors, the 2-year overall survival (OS), progression-free survival (PFS), and locoregional control (LC) for RT/surgery were 97.8%/96.4%, 91.1%/92.0%, and 92.9%/93.3%, respectively. In multivariate analyses, patients with synchronous radiologic extranodal extension and conglomeration (ENEcong) of metastatic lymph nodes (LNs) showed significantly poorer OS (p=0.047), PFS (p=0.001), and LC (p=0.003). In patients undergoing primary surgery, two or more clinically positive LN metastases (odds ratio [OR], 5.15; p=0.004) and LN metastases with ENEcong (OR, 3.75; p=0.009) were predictors of postoperative chemoradiotherapy. No patient in the primary RT group demonstrated late severe toxicity whereas three (2.8%), one (0.9%), and one (0.9%) patient in the surgery group showed grade 3 dysphagia, grade 3 xerostomia, and fatal oral cavity bleeding.
Conclusion We found no differences in OS, PFS, and LC between upfront RT and surgery in stage I-II hpv+OPC which warrants comparison through a prospective trial in the treatment de-escalation era. However, most early-stage hpv+OPC patients undergoing surgery received adjuvant (CC)RT. Pretreatment LN findings were prognostic and predictive for adjuvant treatment.

다국어 초록 (Multilingual Abstract)

Purpose This study aimed to compare the outcomes of primary radiotherapy (RT) versus surgery in early-stage human papilloma virus–positive oropharyngeal squamous cell carcinoma (hpv+OPC), and investigate the preoperative clinical factors that can predict the requirement for postoperative adjuvant treatment.Materials and Methods This multicenter study included 166 patients with American Joint Committee on Cancer 8th edition-Stages I-II hpv+OPC. Sixty (36.1%) and 106 (63.9%) patients underwent primary (concurrent chemo)radiotherapy [(CC)RT] and surgery, respectively. Seventy-eight patients (73.6%) in the surgery group received postoperative (CC)RT.Results With a median follow-up of 45.6 months for survivors, the 2-year overall survival (OS), progression-free survival (PFS), and locoregional control (LC) for RT/surgery were 97.8%/96.4%, 91.1%/92.0%, and 92.9%/93.3%, respectively. In multivariate analyses, patients with synchronous radiologic extranodal extension and conglomeration (ENEcong) of metastatic lymph nodes (LNs) showed significantly poorer OS (p=0.047), PFS (p=0.001), and LC (p=0.003). In patients undergoing primary surgery, two or more clinically positive LN metastases (odds ratio [OR], 5.15; p=0.004) and LN metastases with ENEcong (OR, 3.75; p=0.009) were predictors of postoperative chemoradiotherapy. No patient in the primary RT group demonstrated late severe toxicity whereas three (2.8%), one (0.9%), and one (0.9%) patient in the surgery group showed grade 3 dysphagia, grade 3 xerostomia, and fatal oral cavity bleeding.Conclusion We found no differences in OS, PFS, and LC between upfront RT and surgery in stage I-II hpv+OPC which warrants comparison through a prospective trial in the treatment de-escalation era. However, most early-stage hpv+OPC patients undergoing surgery received adjuvant (CC)RT. Pretreatment LN findings were prognostic and predictive for adjuvant treatment.

참고문헌 (Reference)

• 1 Mirghani H, "Treatment de-escalation for HPV-driven oropharyngeal cancer : where do we stand?" 8 : 4-11, 2018
• 2 Nichols AC, "Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial" 20 : 125-, 2020
• 3 Leonhardt FD, "Transoral robotic surgery for oropharyngeal carcinoma and its impact on patient-reported quality of life and function" 34 : 146-154, 2012
• 4 Baskin RM, "Transoral robotic surgery for oropharyngeal cancer : patient selection and special considerations" 10 : 839-846, 2018
• 5 Haughey BH, "Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer : a United States multicenter study" 33 : 1683-1694, 2011
• 6 Yamashita Y, "Staging and prognosis of oropharyngeal carcinoma according to the 8th edition of the American Joint Committee on Cancer Staging Manual in human papillomavirus infection" 276 : 827-836, 2019
• 7 Peng H, "Significant value of(18)F-FDG-PET/CT in diagnosing small cervical lymph node metastases in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy" 36 : 95-, 2017
• 8 Biau J, "Selection of lymph node target volumes for definitive head and neck radiation therapy : a 2019 update" 134 : 1-9, 2019
• 9 Langendijk JA, "Risk-group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy" 104 : 1408-1417, 2005
• 10 Yom SS, "Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma(NRG Oncology HN-002)" 39 : 956-965, 2021
• 11 Nichols AC, "Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma(ORATOR) : an open-label, phase 2, randomised trial" 20 : 1349-1359, 2019
• 12 Mehanna H, "Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer(De-ESCALaTE HPV) : an open-label randomised controlled phase 3 trial" 393 : 51-60, 2019
• 13 Gillison ML, "Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer(NRG Oncology RTOG 1016) : a randomised, multicentre, non-inferiority trial" 393 : 40-50, 2019
• 14 Billfalk-Kelly A, "Radiologic extranodal extension portends worse outcome in cN+ TNM-8 stage I human papillomavirus-mediated oropharyngeal cancer" 104 : 1017-1027, 2019
• 15 Ozmen OA, "Prognostic significance of soft tissue deposits in laryngeal carcinoma" 84 : 566-573, 2018
• 16 Huang SH, "Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification" 144 : 13-22, 2020
• 17 Boeun Lee ; Young Jun Choi ; Seon-Ok Kim ; Yoon Se Lee ; Jung Yong Hong ; 백정환 ; 이정현, "Prognostic Value of Radiologic Extranodal Extension in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma" 대한영상의학회 20 (20): 1266-1274, 2019
• 18 Geiger JL, "Postoperative treatment of oropharyngeal cancer in the era of human papillomavirus" 20 : 20-, 2019
• 19 Stelmes JJ, "Organ preservation and late functional outcome in oropharyngeal carcinoma : rationale of EORTC 1420, the"Best of"trial" 9 : 999-, 2019
• 20 Morisod B, "Meta-analysis on survival of patients treated with transoral surgery versus radiotherapy for early-stage squamous cell carcinoma of the oropharynx" 38 (38): E2143-E2150, 2016
• 21 Spector ME, "Matted nodes as a predictor of distant metastasis in advanced–stage III/IV oropharyngeal squamous cell carcinoma" 38 : 184-190, 2016
• 22 Cooper JS, "Long-term follow-up of the RTOG 9501/intergroup phase III trial : postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck" 84 : 1198-1205, 2012
• 23 Baliga S, "Identification of clinical and socioeconomic predictors of adjuvant therapy after trans-oral robotic surgery in patients with oropharyngeal squamous cell carcinoma" 12 : 2474-, 2020
• 24 You EL, "Human papillomavirus-associated oropharyngeal cancer : review of current evidence and management" 26 : 119-123, 2019
• 25 Ang KK, "Human papillomavirus and survival of patients with oropharyngeal cancer" 363 : 24-35, 2010
• 26 National Comprehensive Cancer Network, "Head and neck cancers (version 1.2021)" National Comprehensive Cancer Network
• 27 Freitag J, "Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma" 126 : 1856-1872, 2020
• 28 Fundakowski CE, "Considerations in surgical versus non-surgical management of HPV positive oropharyngeal cancer" 1 : 6-, 2016
• 29 이형남 ; 한종규 ; 김형환 ; 신형철 ; 김일영 ; 조성식, "Comparative Study of Lymph Node Metastasis from Squamous Cell Carcinoma and Non-Squamous Cell Carcinoma on Neck CT" 대한영상의학회 72 (72): 271-281, 2015
• 30 Zanoni DK, "Changes in the 8th edition of the American Joint Committee on Cancer(AJCC)staging of head and neck cancer : rationale and implications" 21 : 52-, 2019